Gaetano Bertino: Influence Statistics

Gaetano Bertino

Gaetano Bertino

Department of Experimental and Clinical Medicine, University of Catania, Policlinico “G. Rodolico”, Via S. Sofia n.78, 95123, Catania, Italy | Gastroenterology and Hepatology ...

Gaetano Bertino: Expert Impact

Concepts for which Gaetano Bertino has direct influence: Hepatocellular carcinoma , Chronic hepatitis , Serum levels , Patients chronic hepatitis , Serum markers , Hepatocellular carcinoma hcc , Hepatic coma .

Gaetano Bertino: KOL impact

Concepts related to the work of other authors for which for which Gaetano Bertino has influence: Hepatocellular carcinoma , Hepatorenal syndrome , Chronic hepatitis , Liver disease , Hcc patients , Colorectal cancer , Hcv infection .

KOL Resume for Gaetano Bertino

Year
2022

Department of Experimental and Clinical Medicine, University of Catania, Policlinico “G. Rodolico”, Via S. Sofia n.78, 95123, Catania, Italy

2021

Professor, Department of Clinical and Experimental Medicine, University of Catania

2020

Hepatology Unit, Catania University, Italy

2019

UOC Medicina Interna, AOUP G. Rodolico, Catania, Italy

2018

Department of Experimental and Clinical Medicine, University of Catania, 95123 Catania, Italy;, (G.B.);, (E.V.)

UOC Medicina Interna, AOUP G Rodolico, Catania, Italy

2017

Department of Internal Medicine and Systemic Diseases, University of Catania, 95123 Catania, Italy;,

2016

Gaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.

Hepatology Unit, Department of Clinical and Experimental Medicine, University of Catania, Policlinico “G. Rodolico”, Catania, Italy

2015

Department of Medical and Pediatric Sciences, Hepatology Unit, University of Catania, Policlinic, Via S. Sofia No. 78, 95123 Catania, Italy.

2014

Hepatology Unit, Department of Medical and Pediatric Science, University of Catania, 95100 Catania, Italy

2013

Department of Medical and Pediatric Sciences, Hepatology Unit, University of Catania, 95123 Catania, Italy

2012

Department of Medical and Pediatric Sciences Via S. Sofia, 87, 95123, University of Catania, Italy

2011

Department of Internal Medicine and Systemic diseases, University of Catania, Catania, Italy

2010

Departments of Internal Medicine

Research Center ?The extreme senescence?, University of Catania, Catania, Italy

2009

Department of Internal Medicine, Hospital S Marta University of Catania, Italy;

2008

Department of Internal Medicine and Systemic Diseases, Santa Marta Hospital, University of Catania, Catania, Italy.

2007

Dipartimento di Medicina Interna e Patologie Sistemiche, Ospedale Santa Marta, Università degli Studi di Catania, Italia.

Department of Internal Medicine and Systemic Diseases, Liver Operative Unit, S. Marta Hospital, University of Catania, Catania, Italy

2006

Department of Internal Medicine and Systemic Diseases University of Catania, Catania, Italy.

Prominent publications by Gaetano Bertino

KOL-Index: 16272 . BACKGROUND & AIMS: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus-associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. METHODS: We collected data from a large prospective ...
Known for Patients Svr | Hepatocellular Carcinoma | Daas Hcc | Antiviral Agents
KOL-Index: 16098 . BACKGROUND & AIMS: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic ...
Known for Hcc Recurrence | Acting Antivirals | Hepatic Decompensation | Successful Treatment
KOL-Index: 13624 . BACKGROUND: We evaluated treatment modalities and survival in patients with hepatocellular carcinoma (HCC), by pre-treatment and 3-month post-treatment serum alpha-fetoprotein (AFP) levels and pre-treatment tumor diameters. METHODS: We retrospectively reviewed 57 patients treated for HCC in our department from January 2002 to December 2012, including their sex, type of hepatitis, Child ...
Known for Radiofrequency Ablation | Transarterial Chemoembolization | Tumor Size | Hepatocellular Carcinoma
KOL-Index: 12065 . BACKGROUND: Nonalcoholic fatty liver disease develops in patients with chronic hepatitis C. Interferon and ribavirin combination therapy is the standard treatment for chronic hepatitis C, but if present, NAFLD can reduce the virological response to anti-HCV therapies. OBJECTIVES: We determined whether the addition of rosuvastatin to interferon and ribavirin improves the sustained ...
Known for Chronic Hepatitis | 12 Months | Ribavirin Svr | Fatty Liver
KOL-Index: 9149 . BACKGROUND: Little is known about the association between cigarette smoking and asthma severity. We assessed smoking as a determinant of disease severity and control in a cohort of clinic-referred allergic subjects who developed new onset asthma. METHODS: Allergic rhinitis subjects with no asthma (n = 371) were followed-up for 10 years and routinely examined for asthma diagnosis. In those ...
Known for Smokers Asthma | Allergic Subjects | Cigarette Smoking | Pack Years
KOL-Index: 9066 . BACKGROUND: The health status of employees with chronic hepatitis C has major implications for organizations and labour market. OBJECTIVES: To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin. PATIENTS AND METHODS: In this prospective, ...
Known for Chronic Hepatitis | Hcv Therapy | 12 Months | Carnitine Supplementation
KOL-Index: 9055 . BackgroundHepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life.To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with ...
Known for Work Ability | Depression Anxiety | Chronic Hepatitis | 12 Months
KOL-Index: 8374 . Purpose: Portal vein thrombosis (PVT) is one of the severe complications of hepatocellular carcinoma (HCC). PVT deteriorates the liver, and its dysfunction increases the risk of bleeding, influencing the prognosis of patients with liver cirrhosis and HCC. The aim of our study was to investigate whether D-dimer testing could be a sensitive marker for the diagnosis and prognosis of HCC ...
Known for Portal Vein Thrombosis | Hepatocellular Carcinoma | Hcc Patients Pvt | Sensitive Marker
KOL-Index: 8275 . Purpose: Hepatorenal syndrome (HRS) is a pre-renal-like dysfunction that generally onsets in cirrhotic patients presenting ascites. We investigated the improvement of renal function in subjects with hepatorenal syndrome after terlipressin administration and the survival times after this treatment. Fifty-two patients affected by cirrhosis, with diagnosis of hepatorenal syndrome were treated ...
Known for Renal Function | Patients Cirrhosis | Terlipressin Albumin | Survival Treatment
KOL-Index: 8176 . Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in some areas of the world. In most cases, HCC is diagnosed at a late stage. Therefore, the prognosis of patients with HCC is generally poor. The recommended screening strategy for patients with cirrhosis includes the determination of serum α-fetoprotein (AFP) levels and an abdominal ultrasound every 6 months to ...
Known for Tumor Carcinoma | Patients Hcc | Serum Markers | Early Detection
KOL-Index: 7835 . BACKGROUND: During the past three decades, the incidence of hepatocellular carcinoma in the United States has tripled. The neuroendocrine character has been observed in some tumor cells within some hepatocellular carcinoma nodules and elevated serum chromogranin A also been reported in patients with hepatocellular carcinoma. The aim of this work was to investigate the role of serum ...
Known for Hepatocellular Carcinoma | Serum Levels | Liver Neoplasms | Biomarkers Tumor
KOL-Index: 7400 . INTRODUCTION: The Baveno VI consensus guidelines and an expanded algorithm suggest that transient elastography (TE) and platelet (PLT) count can be used to identify patients with cirrhosis who can avoid esophagogastroduodenoscopy (EGD). The primary aims of this study were to assess the ability of a simple algorithm, which uses only laboratory parameters, to predict medium/large esophageal ...
Known for Transient Elastography | Resisthcv Criteria | Patients Cirrhosis | Validation Cohort

Key People For Hepatocellular Carcinoma

Top KOLs in the world
#1
Jordi Bruix
hepatocellular carcinoma liver transplantation patients hcc
#2
Josep María Llovet
hepatocellular carcinoma advisory consultancy liver transplantation
#3
Vincenzo Mazzaferro
hepatocellular carcinoma liver transplantation patients hcc
#4
Freddie Ian Bray
cancer incidence nordic countries mortality rates
#5
Jacques Ferlay
cancer incidence global burden latin america
#6
Hashem B EL‐SERAG
united states hepatocellular carcinoma veterans affairs

Department of Experimental and Clinical Medicine, University of Catania, Policlinico “G. Rodolico”, Via S. Sofia n.78, 95123, Catania, Italy | Gastroenterology and Hepatology Unit, University Hospital Policlinico Vittorio Emanuele, Catania, Italy | P